In 216 hospitalised patients with acute-on-chronic liver failure and suspected invasive fungal infection, empirical antifungal therapy improved 28-day survival vs diagnostic/biomarker-driven pre-emptive therapy (35% vs 13%; HR 0.64), with fewer adverse events.
RCTn = 216
Verma et al. Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected Invasive Fungal Infections: A Pragmatic Randomized Trial